Barot Dhvani, Usimaki Alexandra, Linardi Renata L, Arensberg Charles M, Ortved Kyla F
Department of Clinical Studies-New Bolton Center, University of Pennsylvania, Kennett Square, PA.
Bessemer Equine, Kennett Square, PA.
Am J Vet Res. 2025 Jan 30;86(4). doi: 10.2460/ajvr.24.11.0363. Print 2025 Apr 1.
Quantify the concentration of α2-macroglobulin (A2M), immunomodulatory cytokines, and TGF-β1 factors in 4 commercially available autologous blood-based products including conditioned A2M (CA2M; Alpha2EQ; Astaria Global), autologous protein solution (APS; Pro-Stride; Zoetis), platelet-rich plasma (PRP; Restigen; Zoetis), and autologous conditioned plasma (ACP; Arthrex ACP). We hypothesized that CA2M would have higher concentrations of A2M and lower concentrations of cytokines and growth factors compared to APS, PRP, and ACP.
Blood was obtained from 6 healthy, adult horses and processed into CA2M, APS, PRP, and ACP. The concentration of immunomodulatory cytokines, including IL-1β, IL-4, IL-6, IL-10, IL-17a, and TNF-α, and the concentration of the growth factor TGF-β1 were quantified using immunoassays. The concentration of the IL-1 receptor antagonist was quantified using ELISA. The concentration of A2M was quantified using mass spectrometry.
No differences in the concentrations of IL-1β, IL-4, IL-6, IL-10, and IL-17a were found. Median TGF-β1 was significantly higher in APS (10,801 pg/mL; P < .05), PRP (6,219 pg/mL; P < .05), and ACP (5,263 pg/mL; P < .05) compared to CA2M (2,090 pg/mL). The IL-1 receptor antagonist was significantly higher in APS (58.78 ng/mL) and PRP (40.45 ng/mL). Median A2M concentration was significantly higher in APS (4.08 mg/mL; P < .001) compared to CA2M (1.99 mg/mL).
Autologous blood-based products have notably different immunomodulatory and growth factor profiles. These differences likely reflect variable concentrations of platelets and WBCs, as well as processing methods.
Equine veterinarians should be aware of the constituents of the different orthobiologics available before use.
对4种市售的基于自体血液的产品中的α2-巨球蛋白（A2M）、免疫调节细胞因子和转化生长因子-β1（TGF-β1）因子浓度进行定量分析，这4种产品包括条件性A2M（CA2M；Alpha2EQ；Astaria Global）、自体蛋白溶液（APS；Pro-Stride；Zoetis）、富血小板血浆（PRP；Restigen；Zoetis）和自体条件血浆（ACP；Arthrex ACP）。我们假设与APS、PRP和ACP相比，CA2M会含有更高浓度的A2M以及更低浓度的细胞因子和生长因子。
从6匹健康成年马采集血液，并加工成CA2M、APS、PRP和ACP。使用免疫测定法定量免疫调节细胞因子的浓度，包括白细胞介素-1β（IL-1β）[插图未找到，请检查]、白细胞介素-4（IL-4）、白细胞介素-6（IL-6）、白细胞介素-10（IL-10）白细胞介素-17a（IL-17a）和肿瘤坏死因子-α（TNF-α），并使用免疫测定法定量生长因子TGF-β1的浓度。使用酶联免疫吸附测定法（ELISA）定量IL-1受体拮抗剂的浓度。使用质谱法定量A2M的浓度。
未发现IL-1β、IL-4、IL-6、IL-10和IL-17a浓度存在差异。与CA2M（2090 pg/mL）相比，APS（10801 pg/mL；P < 0.05）、PRP（6219 pg/mL；P < 0.05）和ACP（5263 pg/mL；P < 0.05）中的TGF-β1中位数显著更高。APS（58.78 ng/mL）和PRP（40.45 ng/mL）中的IL-1受体拮抗剂显著更高。与CA2M（1.99 mg/mL）相比，APS中的A2M浓度中位数显著更高（4.08 mg/mL；P < 0.001）。
基于自体血液的产品具有明显不同的免疫调节和生长因子特征。这些差异可能反映了血小板和白细胞浓度的变化以及加工方法的不同。
马兽医在使用前应了解不同可用的矫形生物制剂的成分。
